# Cancer-specific alterations in nuclear matrix proteins determined by multi-omics analyses of ductal carcinoma in situ

## TL;DR

Researchers identified specific nuclear matrix proteins altered in early breast cancer, which could help determine which cases need aggressive treatment.

## Contribution

The study identifies novel nuclear matrix proteins with altered expression in ductal carcinoma in situ and breast cancer progression.

## Key findings

- Sixty nuclear matrix proteins were differentially expressed in DCIS compared to non-diseased breast tissue.
- Three proteins (RPL7A, RPL11, RPL31) were upregulated in DCIS and all BC stages.
- Three proteins (AHNAK, CDC37, DNAJB1) were downregulated in DCIS and BC stages.

## Abstract

Breast cancer (BC) is the most common cancer affecting women in the United States. Ductal carcinoma in situ (DCIS) is the earliest identifiable pre-invasive BC lesion. Estimates show that 14 to 50% of DCIS cases progress to invasive BC.

Our objective was to identify nuclear matrix proteins (NMP) with specifically altered expression in DCIS and later stages of BC compared to non-diseased breast reduction mammoplasty and a contralateral breast explant culture using mass spectrometry and RNA sequencing to accurately identify aggressive DCIS.

Sixty NMPs were significantly differentially expressed between the DCIS and non-diseased breast epithelium in an isogenic contralateral pair of patient-derived extended explants. Ten of the sixty showed significant mRNA expression level differences that matched the protein expression. These 10 proteins were similarly expressed in non-diseased breast reduction cells. Three NMPs (RPL7A, RPL11, RPL31) were significantly upregulated in DCIS and all other BC stages compared to the matching contralateral breast culture and an unrelated non-diseased breast reduction culture. RNA sequencing analyses showed that these three genes were increasingly upregulated with BC progression. Finally, we identified three NMPs (AHNAK, CDC37 and DNAJB1) that were significantly downregulated in DCIS and all other BC stages compared to the isogenically matched contralateral culture and the non-diseased breast reduction culture using both proteomics and RNA sequencing techniques.

These genes should form the basis of, or contribute to, a molecular diagnostic panel that could identify DCIS lesions likely to be indolent and therefore not requiring aggressive treatment.